News & Updates
Filter by Specialty:
Sexual dysfunction affects >50 percent of patients with schizophrenia
Sexual dysfunction is highly prevalent in schizophrenia, affecting >50 percent of patients. Treatment of comorbid depression may be an effective strategy to improve sexual health, according to a meta-analysis.
Sexual dysfunction affects >50 percent of patients with schizophrenia
09 Nov 2023Brexpiprazole improves agitation in Alzheimer’s dementia
A double-blind, placebo-controlled, randomized clinical trial reports significant improvement in agitation with brexpiprazole vs placebo among patients with Alzheimer’s dementia.
Brexpiprazole improves agitation in Alzheimer’s dementia
09 Nov 2023IBS symptoms tied to depression, anxiety in NAFLD patients
Patients with nonalcoholic fatty liver disease (NAFLD) tend to have higher rates of irritable bowel syndrome (IBS) symptoms, depression, and anxiety, suggests a study.
IBS symptoms tied to depression, anxiety in NAFLD patients
04 Nov 2023Esketamine outperforms quetiapine in head-to-head depression trial
In patients with treatment-resistant depression, esketamine nasal spray appears to have superior efficacy compared with extended-release quetiapine when used in combination with conventional antidepressants.
Esketamine outperforms quetiapine in head-to-head depression trial
30 Oct 2023Adult ADHD spells increased dementia risk
Adults with attention-deficit/hyperactivity disorder (ADHD) face a nearly threefold higher risk of dementia compared with those who do not have the neurodevelopmental condition, according to a study.
Adult ADHD spells increased dementia risk
22 Oct 2023Postpartum depression more common in pregnant women with rheumatic disease
Women of reproductive age with axial spondyloarthritis (axSpA), psoriatic arthritis (PsA), or rheumatoid arthritis (RA) are more likely to experience postpartum depression than those without any rheumatic disease (RD), according to a study.
Postpartum depression more common in pregnant women with rheumatic disease
19 Oct 2023Antipsychotic dose reduction in recurrent psychosis: No clear benefits but increased relapse risk
Gradual antipsychotic dose reduction does not provide benefits in social functioning and is associated with an increased risk of relapse in patients with schizophrenia, the RADAR trial has shown.
Antipsychotic dose reduction in recurrent psychosis: No clear benefits but increased relapse risk
09 Oct 2023COVID vs non-COVID ARDS: Are both mentally distressing for patients’ kin?
Mental health symptoms of family members of patients hospitalized for acute respiratory distress syndrome (ARDS) were similar at 12 months regardless of whether it was caused by COVID-19 or not, a prospective cohort study suggests.